Table 5.

Incidences of less common AEs

	Incidence
	Canagliflozin 100 mg	Canagliflozin 300 mg	Placebo	Population	Study
Renal-related AE	2.60%a	2.80%a	2.80%	Pooled analysis of patients taking canagliflozin 100 mg or 300 mg up to 104 weeks	Desai et al, 201733
Fracture	2.70%b	2.70%c	1.90%	Pooled analysis of patients taking canagliflozin 100 mg or 300 mg with a mean exposure of 116 weeks	Watts et al, 201628
DKA	0.07%d	0.11%d	0.03%	Pooled analysis of patients taking canagliflozin 100 mg or 300 mg with a mean exposure of 72 weeks	Erondu et al, 201534
Amputation	0.02%e,f	0.02%e,f	0.01%	Single study followed for a mean of 188 weeks	Neal et al, 201714

Note:

^aNo statistical difference;

^bHR 1.28 (95% CI: 0.93–1.77);

^cHR 1.34 (CI: 0.98–1.84);

^dno P-value of HR reported;

^eP<0.001;

^fdata unavailable regarding dosage of 100 mg or 300 mg of canagliflozin.

Abbreviations: AEs, adverse events; DKA, diabetic ketoacidosis.